Atracurium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Atracurium
Accession Number
DB13295
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description
Not Available
Synonyms
Not Available
Categories
UNII
2GQ1IRY63P
CAS number
64228-79-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Atracurium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetyldigitoxinAtracurium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinAtracurium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclarubicinAclarubicin may increase the respiratory depressant activities of Atracurium.Investigational
AclidiniumAtracurium may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Atracurium is combined with Alcuronium.Experimental
AldoxorubicinAldoxorubicin may increase the respiratory depressant activities of Atracurium.Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Atracurium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Atracurium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Atracurium is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Ambenonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Atracurium.Approved, Investigational, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Atracurium.Approved
AnnamycinAnnamycin may increase the respiratory depressant activities of Atracurium.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Atracurium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Atracurium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Atracurium.Approved, Vet Approved
AzosemideAzosemide may decrease the neuromuscular blocking activities of Atracurium.Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Atracurium.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Atracurium.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Atracurium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Atracurium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Atracurium.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Atracurium.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational
Botulinum Toxin Type BAtracurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BumetanideBumetanide may decrease the neuromuscular blocking activities of Atracurium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Atracurium is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Atracurium.Approved, Investigational, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Atracurium.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Atracurium is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Atracurium.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Atracurium.Approved
CimetropiumAtracurium may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
ClindamycinClindamycin may increase the neuromuscular blocking activities of Atracurium.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Atracurium is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Atracurium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Atracurium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Atracurium.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Atracurium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational, Vet Approved
CymarinAtracurium may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Atracurium.Approved
DecamethoniumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Atracurium.Approved
DeslanosideAtracurium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Atracurium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Atracurium.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Atracurium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Atracurium is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Atracurium is combined with Dezocine.Approved, Investigational
DibekacinDibekacin may increase the respiratory depressant activities of Atracurium.Experimental
DichlorvosThe therapeutic efficacy of Atracurium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Atracurium.Approved
DigitoxinAtracurium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinAtracurium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Atracurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Atracurium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Atracurium.Investigational, Vet Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Atracurium.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Atracurium is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Atracurium can be decreased when used in combination with Donepezil.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Atracurium is combined with DPDPE.Experimental
DronabinolAtracurium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Atracurium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Edrophonium.Approved
EluxadolineAtracurium may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Atracurium is combined with Emepronium.Experimental
EpirubicinEpirubicin may increase the respiratory depressant activities of Atracurium.Approved
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Atracurium.Experimental
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Atracurium is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Atracurium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Atracurium is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Atracurium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Atracurium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Atracurium.Approved
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Atracurium.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Atracurium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Atracurium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Atracurium is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Atracurium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Atracurium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Atracurium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Atracurium.Experimental
GitoformateAtracurium may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Atracurium is combined with Glucagon recombinant.Approved
GlycopyrroniumAtracurium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GPX-150GPX-150 may increase the respiratory depressant activities of Atracurium.Investigational
HeroinThe risk or severity of adverse effects can be increased when Atracurium is combined with Heroin.Approved, Illicit, Investigational
HomatropineThe risk or severity of adverse effects can be increased when Atracurium is combined with Homatropine.Approved
Human secretinThe therapeutic efficacy of Human secretin can be decreased when used in combination with Atracurium.Approved
Huperzine AThe therapeutic efficacy of Atracurium can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Atracurium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atracurium.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Atracurium is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Atracurium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Atracurium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Atracurium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Atracurium.Approved
IpidacrineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Atracurium.Experimental
IsoflurophateThe therapeutic efficacy of Atracurium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Atracurium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Atracurium.Approved, Investigational, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Atracurium is combined with Ketobemidone.Approved, Investigational
Lanatoside CAtracurium may increase the arrhythmogenic activities of Lanatoside C.Experimental
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Atracurium is combined with Levorphanol.Approved
LincomycinLincomycin may increase the neuromuscular blocking activities of Atracurium.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Atracurium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Atracurium is combined with Lofentanil.Illicit
LorpiprazoleThe therapeutic efficacy of Atracurium can be increased when used in combination with Lorpiprazole.Approved
Magnesium hydroxideMagnesium hydroxide may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Atracurium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Atracurium.Approved
Magnesium sulfateMagnesium sulfate may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational, Vet Approved
MalathionThe therapeutic efficacy of Atracurium can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Atracurium is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium.Approved, Investigational
MefloquineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Mefloquine.Approved, Investigational
MemantineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Atracurium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Atracurium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Atracurium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Atracurium.Approved, Investigational
MethscopolamineThe risk or severity of adverse effects can be increased when Atracurium is combined with Methscopolamine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Atracurium.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Atracurium is combined with Methylscopolamine bromide.Approved
MetildigoxinAtracurium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Atracurium is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Atracurium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Atracurium.Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Atracurium.Approved
MianserinMianserin may increase the anticholinergic activities of Atracurium.Approved, Investigational
MicronomicinMicronomicin may increase the respiratory depressant activities of Atracurium.Experimental
MinaprineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Atracurium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Morphine.Approved, Investigational
NabiloneAtracurium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Atracurium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Atracurium.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Atracurium is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Atracurium is combined with Normethadone.Approved, Illicit
OleandrinAtracurium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OpiumThe risk or severity of adverse effects can be increased when Atracurium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Atracurium.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Atracurium is combined with Otilonium.Experimental, Investigational
OuabainAtracurium may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Atracurium is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Atracurium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Atracurium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Atracurium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Atracurium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Atracurium.Approved
ParaoxonThe therapeutic efficacy of Atracurium can be decreased when used in combination with Paraoxon.Experimental
ParomomycinParomomycin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Atracurium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Atracurium.Approved
PeruvosideAtracurium may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Atracurium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Atracurium is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Atracurium.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Atracurium is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Physostigmine.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Atracurium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Atracurium.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Atracurium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Atracurium is combined with Piritramide.Approved, Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Atracurium.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Atracurium.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Atracurium.Approved, Investigational, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Atracurium.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Atracurium.Approved
Potassium ChlorideAtracurium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Atracurium.Approved, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Atracurium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Atracurium.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Atracurium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Atracurium.Approved, Investigational
ProscillaridinAtracurium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Atracurium.Experimental
PyridostigmineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Atracurium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Atracurium.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Atracurium.Approved
RamosetronAtracurium may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Atracurium is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
RivastigmineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Rivastigmine.Approved, Investigational
SabarubicinSabarubicin may increase the respiratory depressant activities of Atracurium.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium.Approved, Investigational
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Atracurium.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Atracurium.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Atracurium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Atracurium.Approved, Investigational, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Atracurium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Atracurium is combined with Sufentanil.Approved, Investigational
SulpirideAtracurium may increase the anticholinergic activities of Sulpiride.Approved, Investigational
TacrineThe therapeutic efficacy of Atracurium can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Atracurium is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Atracurium is combined with Tilidine.Experimental
TiotropiumAtracurium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Atracurium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Atracurium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Atracurium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Atracurium.Approved
TramadolThe risk or severity of adverse effects can be increased when Atracurium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Atracurium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Atracurium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Atracurium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Atracurium.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Atracurium is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Atracurium.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Atracurium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Atracurium.Approved
TyrothricinThe therapeutic efficacy of Atracurium can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumAtracurium may increase the anticholinergic activities of Umeclidinium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Atracurium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Atracurium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Atracurium.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the respiratory depressant activities of Atracurium.Investigational
ZorubicinZorubicin may increase the respiratory depressant activities of Atracurium.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Atracurium
ATC Codes
M03AC04 — Atracurium

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedNot AvailableIntraocular Pressure1
3CompletedDiagnosticPostoperative pain1
4CompletedDiagnosticAtracurium / Cefazolin / Morphine / Nadroparin / Obese1
4CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
4CompletedTreatmentTracheal Intubation1
4Not Yet RecruitingOtherPatients Undergoing Laparoscopic Surgery1
Not AvailableCompletedSupportive CareRobot-Assisted Laparoscopic Radical Prostatectomy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:39 / Updated on May 02, 2018 00:31